Vitamin D and cardiovascular risk among adults with obesity: A systematic review and meta-analysis

European Journal of Clinical Investigation

Volumn 45, Issue 10, 2015, Pages 1113-1126

  Manousopoulou, Antigoni ^a   Al Daghri, Nasser M ^b,c   Garbis, Spiros D ^a   Chrousos, George P ^c,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiometabolic profile; Cardiovascular risk; Obesity; Vitamin D

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VITAMIN D; CALCIUM; GLUCOSE BLOOD LEVEL; VITAMIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUN EXPOSURE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; FEMALE; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SUNLIGHT; VITAMIN D DEFICIENCY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SUNLIGHT; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84941950517     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12510     Document Type: Review

References (46)

1. World Health Organization (WHO). Global Status Report on Noncommunicable Diseases 2010. Geneva: WHO, 2011.
2. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000;85:251-5.
3. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40.
4. Middelbeek RJ, Horton ES. The role of glucose as an independent cardiovascular risk factor. Curr Diab Rep 2007;7:43-9.
5. Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol 2013;168:4761-8.
6. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013;12:976-89.
7. O'Keefe JH, Lavie CJ, Holick MF. Vitamin D supplementation for cardiovascular disease prevention. JAMA 2011;306:1546-7; author reply 7-8.
8. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1-23.
9. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015;178:111-6.
10. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035.
11. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009;57:1595-603.
12. Perna L, Schöttker B, Holleczek B, Brenner H. Serum 25-hydroxyvitamin d and incidence of fatal and nonfatal cardiovascular events: a prospective study with repeated measurements. J Clin Endocrinol Metab 2013;98:4908-15.
13. Elamin MB, Abu-Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931-42.
14. Saneei P, Salehi-Abargouei A, Esmaillzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis. Obes Rev 2013;14:393-404.
15. Saliba W, Barnett-Griness O, Rennert G. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. Osteoporos Int 2013;24:1447-54.
16. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-3.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.
18. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
19. Critical Appraisal Skills Programme (CASP). CASP Checklists. Randomised Control Trial. URL: http://www.casp-uk.net/#!casp-tools-checklists/c18f8. Access date: 26 March 2014.
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
21. Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. Am J Clin Nutr 2014;99:1015-25.
22. Wamberg L, Kampmann U, Stødkilde-Jørgensen H, Rejnmark L, Pedersen SB, Richelsen B. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med 2013;24:644-9.
23. Carillo AE, Flynn MG, Pinkston C, Markofski MM, Jiang Y, Donkin SS et al. Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults. Clin Nutr 2012;32:375-81.
24. Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, Amiri F. Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial. Diabet Med 2013;30:1477-81.
25. 3 supplementation on body fat mass in healthy overweight and obese women. J Nutr 2012;11:78.
26. 3 and the risk of CVD in overweight and obese women: a randomised controlled trial. Br J Nutr 2012;108:1866-73.
27. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. Int J Food Sci Nutr 2011;62:318-27.
28. Zhou J, Zhao LJ, Watson P, Zhang Q, Lappe JM. The effect of calcium and vitamin D supplementation on obesity in postmenopausal women: secondary analysis for a large-scale, placebo controlled, double-blind, 4 year longitudinal clinical trial. Nutr Metab (Lond) 2010;7:62.
29. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009;26:19-27.
30. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009;89:1321-7.
31. Kamycheva E, Berg V, Jorde R. Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects. Endocrine 2013;43:412-8.
32. Beilfuss J, Berg V, Sneve M, Jorde R, Kamycheva E. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine 2012;60:870-4.
33. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010;267:462-72.
34. Jorde R, Sneve M, Torjesen P, Figenschau Y, Goransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010;50:175-80.
35. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol 2008;159:675-84.
36. Zhou JC, Zhu YM, Guo P, Chen Z, Xie FZ, Liu XL et al. Serum 25(OH)D and Lipid Levels in Chinese Obese and Normal Weight Males before and after Oral Vitamin D Supplementation. Biomed Environ Sci 2013;26:801-7.
37. Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metabolism 2012;61:661-6.
38. Chao YS, Brunel L, Faris P, Veugelers PJ. The importance of dose, frequency and duration of vitamin D supplementation for plasma 25-hydroxyvitamin D. Nutrients 2013;5:4067-78.
39. Glade MJ. A 21st century evaluation of the safety of oral vitamin D. Nutrition 2012;28:344-56.
40. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98:920-5.
41. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
42. World Health Federation. Fact Sheets. Cardiovascular risk factors. URL: http://www.world-heart-federation.org/press/fact-sheets/cardiovascular-disease-risk-factors/. Access date: 25 March 2014.
43. Spoletini I, Caprio M, Vitale C, Rosano GM. Androgens and cardiovascular disease: gender-related differences. Menopause Int 2013;19:82-6.
44. Al-Daghri NM, Al-Attas OS, Johnston HE, Singhania A, Alokail MS, Alkharfy KM et al. Whole serum 3D LC-nESI-FTMS quantitative proteomics reveals sexual dimorphism in the milieu intérieur of overweight and obese adults. J Proteome Res 2014;13:5094-105.
45. Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 2012;36:387-96.
46. Al-Daghri NM, Garbis SD. The need for serological markers of response to vitamin D status optimization: a case for quantitative serum proteomics. Bioanalysis 2014;6:721-3.